SEC Form 4 · accession 0001209191-18-008548
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Graney
Officer — Chief Financial Officer
Period of report
Feb 6, 2018
Accepted (ET)
Feb 8, 2018 · 6:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 6, 2018 | A | 4,500 | $0.00 | A | 13,289 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $155.57 | Feb 6, 2018 | A | 10,436 | A | — | Feb 5, 2028 | Common Stock | 10,436 | 10,436 | D |
Explanation of responses
- F1Restricted stock unit award that vests in three equal installments on 2/17/2019, 2/17/2020 and 2/17/2021.
- F2The option vests in 16 quarterly installments from 2/6/2018.